1368-0104: Efficacy and safety of spesolimab in patients with Netherton syndrome

• Research type

  Research Study

• Full title

  Evasayil : A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome

• IRAS ID

  1007215

• Contact name

  Medical Information

• Contact email

  medinfo.bra@boehringer-ingelheim.com

• Sponsor organisation

  Boehringer Ingelheim Limited

• Research summary

  A study to test whether spesolimab helps people with skin disease called Netherton syndrome
  The primary objective is to evaluate the treatment response of spesolimab (determined by 50% improvement at Week 16 in IASI score).

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  23/EE/0070

• Date of REC Opinion

  3 Oct 2023

• REC opinion

  Further Information Favourable Opinion